Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6957040cd6075e8cdf2616604541e93f |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-14 |
filingDate |
2019-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dccbfba51e423fdd157a923810b77a23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c7dcd49fe4969a392b9f6938a421c10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a58100fc9754aa29ce0da8dad1d4f59d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38be17503baca84228e72ab2f1658c30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41d918ad51d1c4d1a1b4e39a557bc40d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea5cee12be091dd4b8c46d38c7051bba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6125ea8474dda8f70283d29044264992 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db6bd01b01f02564f4041c2d787f4847 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_194a24f37f208d99b8c36d2e9bafbbfe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43aa0522fb1f03a93b281f360635c49d |
publicationDate |
2021-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3915539-A1 |
titleOfInvention |
Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent |
abstract |
The invention relates to an aqueous ophthalmic pharmaceutical composition comprising: na) at least 0.4% w/v of bilastine, of formulan nor a pharmaceutically acceptable salt or solvate thereof, wherein the bilastine salt or solvate thereof is completely dissolved in the pharmaceutical composition; nb) at least one β-cyclodextrin; and nc) at least one pharmaceutically acceptable water-soluble gelling agent; nand wherein the pH is comprised between 4 and 9. nand its use in the treatment and/or prevention of conditions mediated by H 1 histamine receptor, such as allergic disorders or diseases. The invention relates to the treatment and/or prevention of allergic conjunctivitis. |
priorityDate |
2018-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |